Bibliography
- Takamatsu H, Kumanogoh A. Diverse roles for semaphorin-plexin signaling in the immune system. Trends Immunol 2012;33(3):127-35
- Negishi-Koga T, Shinohara M, Komatsu N, et al. Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat Med 2011;17(11):1473-80
- Dacquin R, Domenget C, Kumanogoh A, et al. Control of bone resorption by semaphorin 4D is dependent on ovarian function. PLoS One 2011;6(10):e26627
- Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356(18):1809-22
- Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361(8):756-65
- Neer R, Arnaud C, Zanchetta J, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344(19):1434-41
- Makras P, Vaiopoulos G, Lyritis GP. 2011 guidelines for the diagnosis and treatment of osteoporosis in Greece. J Musculoskelet Neuronal Interact 2012;12(1):38-42
- Negishi-Koga T, Takayanagi H. Bone cell communication factors and Semaphorins. Bonekey Rep 2012;1:183
- Anastasilakis AD, Polyzos SA, Gkiomisi A, et al. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naïve postmenopausal women with low bone mass: a randomized, head-to-head clinical trial. J Clin Endocrinol Metab 2013;98(8):3206-12
- Zhang Y, Wei L, Miron RJ, et al. Anabolic bone formation via a site specific bone targeting delivery system by interfering with semaphorin 4D expression. J Bone Miner Res 2014; Epub ahead of print
- Uyanne J, Calhoun CC, Le AD. Antiresorptive drug-related osteonecrosis of the jaw. Dent Clin North Am 2014;58(2):369-84
- Pazianas M, Smith R. Commentary: drug-associated atypical femoral fractures (DaAFFs): balancing the facts. J Clin Endocrinol Metab 2014;99(7):2340-2